Clinical trials: Disorder, Mood
Major Depressive Disorder
Safety of REL-1017 for Major Depressive Disorder
This was a 1-year, multicenter, open-label, long-term study to assess the safety of REL-1017 once daily (QD) as monotherapy or as adjunctive treatment of Major Depressive Disorder.
- Trial name
- RELIANCE-OLS (NCT04855760)
- Testing
- REL-1017
- Where
- 9 sites in United States
- Volunteers
- 627 people
- Sponsor
- Relmada Therapeutics, Inc.
Depressive Disorder, Anhedonia
Study to Treat Major Depressive Disorder With a New Medication
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga…
- Trial name
- NCT03043560
- Testing
- Ezogabine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- James Murrough
Bipolar Disorder, Mixed Mania
Allopurinol Add-on Treatment for Refractory Mania
The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania.
- Conditions
- Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
- Trial name
- NCT00643123
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cedars-Sinai Medical Center
Major Depressive Disorder
Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.
- Trial name
- NCT00529789
- Testing
- duloxetine
- Where
- 22 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02218008
- Testing
- ALKS 5461
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 407 people
- Sponsor
- Alkermes, Inc.
Bipolar Disorder, Depression
A Trial of SAMe for Treatment-Resistant Bipolar Depression
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants.
- Conditions
- Bipolar Disorder, Depression, Bipolar Depression
- Trial name
- NCT00762268
- Testing
- SAMe
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mclean Hospital
Major Depression
Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
The antidepressant medications are among the most commonly prescribed pharmacological agents in patients with mood and anxiety disorder.
- Trial name
- NCT03927950
- Testing
- escitalopram, bupropion
- Where
- Estonia
- Volunteers
- 135 people
- Sponsor
- University of Tartu
Major Depressive Disorder
A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic
Despite large-scale, nationwide efforts to better address suicidal behavior in Veterans at high risk, the development of interventions that target some of the key risk factors associated with suicide remains limited.
- Trial name
- CogRemVet (NCT04952532)
- Testing
- Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Depression
Emotional and Cognitive Control in Late-Onset Depression
This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.
- Trial name
- NCT01728194
- Testing
- Escitalopram, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Bipolar Depression
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
The goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, the project focuses on the importance of dopamine signaling in the process.
- Trial name
- NCT03902613
- Testing
- Lurasidone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New York State Psychiatric Institute
Bipolar I Disorder
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
This is an open-label, multi-center,12 week extension study designed to evaluate the longer term safety, tolerability and effectiveness of lurasidone, flexibly dosed, adjunctive to lithium or divalproex for the treatment of…
- Trial name
- PERSISTExt (NCT01575561)
- Testing
- Lurasidone
- Where
- 71 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Disorder, Major Depressive Episode
Ketamine for Suicidality in Bipolar Depression
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from bipolar depression.
- Conditions
- Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- NCT01944293
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression (Pilot)
Treatment resistant depression (TRD) is a major public health problem. Current therapeutic options for this patient population remain limited.
- Trial name
- NCT01179009
- Testing
- Ketamine, Clonidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder.
- Trial name
- Reliance I (NCT04688164)
- Testing
- REL-1017
- Where
- 11 sites in United States
- Volunteers
- 227 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.
- Trial name
- NCT06309277
- Testing
- GM-1020
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Gilgamesh Pharmaceuticals
Bipolar Disorder
N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
We propose to conduct a double-blind placebo-controlled trial with a widely available and prototypical non-steroidal anti-inflammatory agent, aspirin, and an antioxidant agent, NAC, involving symptomatic Bipolar Disorder type I…
- Trial name
- SMRI-Bipolar (NCT01797575)
- Testing
- Aspirin, N-acetyl-cysteine (NAC), Sugar Pill
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- The University of Texas Health Science Center, Houston
Major Depressive Disorder
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed…
- Trial name
- NCT02356107
- Testing
- 5-hydroxytryptophan and Creatine monohydrate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depressive Disorder, Bipolar Disorder
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological…
- Trial name
- NCT00581009
- Testing
- chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Major Depressive Disorder
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
- Trial name
- NCT02972632
- Testing
- Vortioxetine
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.